FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2297988161> ?p ?o ?g. }

• W2297988161 endingPage "10050" @default.
• W2297988161 startingPage "10050" @default.
• W2297988161 abstract "10050 Background: CNS relapse in high-risk NB is on the rise as extracranial disease control improves. Management of CNS relapse with radiotherapy (RT) that does not address the entire neuraxis has been ineffective in preventing further progression and ultimate death. The purpose of the present study is to describe the use of craniospinal irradiation (CSI) for CNS relapse in high-risk NB and compare outcomes to a historical cohort of patients who did not receive CSI. Methods: A retrospective query identified 24 children with high- risk NB treated at MSKCC since 1987 who received RT for CNS relapse. All patients received appropriate initial therapies and were in remission at the time of CNS recurrence. 14 patients received CSI, and 10 received focal RT that did not address the entire neuraxis. CSI was delivered to a median dose of 2160 cGy, and 10 patients received a boost to a median dose of 2520 cGy. Of those who underwent CSI, 13 (93%) received intrathecal (IT) immunotherapy with 131I-8H9 or 131I-3F8. None of the patients in the non-CSI cohort received IT immunotherapy. Results: The demographic and relapse characteristics were similar between the two groups with the exception that patients who underwent CSI represented a more modern cohort. The age at and time to CNS relapse was 5 and 1.5 years, respectively, in both cohorts. At a median follow-up of 18.3 months (range 1.5–53) after CNS relapse, 10 (71%) patients in the CSI group are alive without evidence of disease. In contrast, all 10 patients in the non-CSI cohort died of disease at a median of 8.1 months (range 4.2–12.9). One patient in the CSI cohort died 1.5 years after CNS relapse of progressive leptomeningeal disease; this was also the only patient in that cohort who did not receive IT immunotherapy. One patient in the CSI cohort died 22 months after CNS relapse of unrelated causes. Two patients developed bone recurrence, but remain free of CNS disease. Conclusions: Based on this small cohort of patients, low-dose CSI in conjunction with IT immunotherapy provides durable CNS remissions and improved survival relative to the experience with focal RT and conventional therapies alone. Further evaluation of long-term NB survivors after CSI is warranted to determine the unique long-term treatment consequences for this young patient cohort. No significant financial relationships to disclose." @default.
• W2297988161 created "2016-06-24" @default.
• W2297988161 creator A5001394511 @default.
• W2297988161 creator A5043729995 @default.
• W2297988161 creator A5050235191 @default.
• W2297988161 creator A5050680844 @default.
• W2297988161 creator A5058658514 @default.
• W2297988161 creator A5082203841 @default.
• W2297988161 creator A5049280981 @default.
• W2297988161 date "2008-05-20" @default.
• W2297988161 modified "2023-10-04" @default.
• W2297988161 title "Whole neuraxis irradiation to address central nervous system (CNS) relapse in high-risk neuroblastoma (NB)" @default.
• W2297988161 doi "https://doi.org/10.1200/jco.2008.26.15_suppl.10050" @default.
• W2297988161 hasPublicationYear "2008" @default.
• W2297988161 type Work @default.
• W2297988161 sameAs 2297988161 @default.
• W2297988161 citedByCount "0" @default.
• W2297988161 crossrefType "journal-article" @default.
• W2297988161 hasAuthorship W2297988161A5001394511 @default.
• W2297988161 hasAuthorship W2297988161A5043729995 @default.
• W2297988161 hasAuthorship W2297988161A5049280981 @default.
• W2297988161 hasAuthorship W2297988161A5050235191 @default.
• W2297988161 hasAuthorship W2297988161A5050680844 @default.
• W2297988161 hasAuthorship W2297988161A5058658514 @default.
• W2297988161 hasAuthorship W2297988161A5082203841 @default.
• W2297988161 hasConcept C126322002 @default.
• W2297988161 hasConcept C141071460 @default.
• W2297988161 hasConcept C143998085 @default.
• W2297988161 hasConcept C167135981 @default.
• W2297988161 hasConcept C509974204 @default.
• W2297988161 hasConcept C529278444 @default.
• W2297988161 hasConcept C71924100 @default.
• W2297988161 hasConcept C72563966 @default.
• W2297988161 hasConceptScore W2297988161C126322002 @default.
• W2297988161 hasConceptScore W2297988161C141071460 @default.
• W2297988161 hasConceptScore W2297988161C143998085 @default.
• W2297988161 hasConceptScore W2297988161C167135981 @default.
• W2297988161 hasConceptScore W2297988161C509974204 @default.
• W2297988161 hasConceptScore W2297988161C529278444 @default.
• W2297988161 hasConceptScore W2297988161C71924100 @default.
• W2297988161 hasConceptScore W2297988161C72563966 @default.
• W2297988161 hasIssue "15_suppl" @default.
• W2297988161 hasLocation W22979881611 @default.
• W2297988161 hasOpenAccess W2297988161 @default.
• W2297988161 hasPrimaryLocation W22979881611 @default.
• W2297988161 hasRelatedWork W1586374228 @default.
• W2297988161 hasRelatedWork W2003938723 @default.
• W2297988161 hasRelatedWork W2047967234 @default.
• W2297988161 hasRelatedWork W2118496982 @default.
• W2297988161 hasRelatedWork W2364998975 @default.
• W2297988161 hasRelatedWork W2369162477 @default.
• W2297988161 hasRelatedWork W2439875401 @default.
• W2297988161 hasRelatedWork W2603773853 @default.
• W2297988161 hasRelatedWork W4238867864 @default.
• W2297988161 hasRelatedWork W2525756941 @default.
• W2297988161 hasVolume "26" @default.
• W2297988161 isParatext "false" @default.
• W2297988161 isRetracted "false" @default.
• W2297988161 magId "2297988161" @default.
• W2297988161 workType "article" @default.